KEEGAN COLLINS: Open Payments
NPI 1407331747 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 6 payments from 5 companies in 2025. Trend: 2023 $916 · 2024 $143 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 2 | $249 |
| Boston Scientific Corporation | 1 | $174 |
| Fresenius Kabi USA, LLC | 1 | $123 |
| Mallinckrodt Hospital Products Inc. | 1 | $108 |
| ABBVIE INC. | 1 | $18 |
Products named: ZERBAXA, FARAPULSE, Smoflipid, TERLIVAZ, TEFLARO.
Industry payments across TX — which companies pay providers there.
